Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Home
<
List for "S01LA" (16)
–
Sort according to Concentration, Size and Price
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Package Size
EFP
CP
SB
DC
Composition
Registr. Holder
Category
Verteporfin (S01LA01) 1 products
WHO-DDD
DrugBank.ca
L
IP
CI
Visudyne
ampoule(s)
1157.25
1275.00
10 %
Lyophilisate: Verteporfinum 15 mg
Cheplapharm Schweiz
GmbH
A / SL
FB
G
Ranibizumab (S01LA04) 9 products
WHO-DDD
DrugBank.ca
L
IP
Ranivisio 10 mg/mL
555.54
620.60
10 %
Injection solution: Ranibizumabum 10 mg/ml
Bioeq AG
B / SL
FB
G
L
IP
Ximluci 10 mg/ml
481.46
544.60
10 %
Injection solution: Ranibizumabum 10 mg/ml
Spirig HealthCare AG
B / SL
FB
G
IP
Byooviz 10 mg / mL
PR
PR
k.A.
Injection solution: Ranibizumabum 10 mg/ml
Samsung Bioepis CH
GmbH
B
FB
G
IP
Ximluci 10 mg/ml
PR
PR
k.A.
Injection solution: Ranibizumabum 10 mg/ml
Spirig HealthCare AG
B
FB
G
L
IP
Byooviz 10 mg / mL
555.54
620.60
10 %
Injection solution: Ranibizumabum 10 mg/ml
Samsung Bioepis CH
GmbH
B / SL
FB
G
L
SIP
IP
CI
Lucentis
Durchstechflasche(n) à 0.23 ml
611.09
677.60
10 %
Injektionslösung zur intravitrealen Injektion in Durchstechflasche: Ranibizumabum 10 mg/ml
Novartis Pharma
Schweiz AG
B / SL
FB
G
L
IP
Lucentis
Fertigspritze(n)
611.09
677.60
10 %
Injektionslösung zur intravitrealen Injektion in Fertigspritze: Ranibizumabum 10 mg/ml
Novartis Pharma
Schweiz AG
B / SL
FB
G
SIP
IP
CI
Lucentis
Durchstechflasche(n) à 0.23 ml
874.34
1020.15
k.A.
Injektionslösung zur intravitrealen Injektion in Durchstechflasche: Ranibizumabum 10 mg/ml
Novartis Pharma
Schweiz AG
B
FB
G
SIP
IP
CI
Lucentis
Durchstechflasche(n) à 0.23 ml
PR
PR
k.A.
Injektionslösung zur intravitrealen Injektion in Durchstechflasche: Ranibizumabum 10 mg/ml
Novartis Pharma
Schweiz AG
B
FB
G
Aflibercept (S01LA05) 5 products
WHO-DDD
DrugBank.ca
L
IP
PP
Eylea 8 mg/0.07 ml
845.90
936.40
10 %
Injection solution: Afliberceptum 8mg / 0.07ml
Bayer (Schweiz) AG
B / SL
FB
G
L
IP
PP
Eylea 8 mg/0.07ml
845.90
936.40
10 %
Injection solution in prefilled syringe: Afliberceptum 8mg / 0.07ml
Bayer (Schweiz) AG
B / SL
FB
G
L
IP
PP
Eylea, 2 mg/0,05 ml
Durchstechflasche(n)
845.90
936.40
10 %
Injection solution: Afliberceptum 2mg / 0.05ml
Bayer (Schweiz) AG
B / SL
FB
G
L
IP
PP
Eylea 2 mg/0.05 ml
845.90
936.40
10 %
Lösung zur intravitrealen Injektion in einer Fertigspritze: Afliberceptum 2mg / 50µl
Bayer (Schweiz) AG
B / SL
FB
G
IP
PP
Eylea 2 mg/0.05 ml
syringe(s)
913.48
1063.35
k.A.
Lösung zur intravitrealen Injektion in einer Fertigspritze: Afliberceptum 2mg / 50µl
Bayer (Schweiz) AG
B
FB
G
Brolucizumab (S01LA06) 1 products
WHO-DDD
L
IP
Beovu 120mg/1ml
652.91
726.50
10 %
Injection solution in prefilled syringe: Brolucizumabum 120 mg/ml
Novartis Pharma
Schweiz AG
B / SL
FB
G
show caption
Red = Original
CM
= Co-Marketing
EFP = Ex-Factory-Price, exkl. VAT CHF
Green = Generic Drug
V/S
= vaccine/blood product
CP = Consumer Price, inkl. VAT CHF
Black = not classified
A
= Anesthetic
PR = Price request
Gray background = Pending Permission Extension
SIP
= Short Information for Professionals
SB = Selbstbehalt
H
= Homeopathics
IP
= Information for Professionals
DC = Daily Cost
A
= Anthroposophics
CI
= Consumer Information
SL = Official reimbursement list of Switzerland.
Ph
= Phytotherapeutics
L
= Limitations
SO = Original according to SL
Cas Reg.Nr. = CAS Registry
G
= Google Search by Product Name
SG = Generic according to SL
P
= Import parallel
FB
= Drugs Feedback
LPPA = Liste des produits pharmaceutiques pour application spéciale
Legal Disclaimer
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2025
©ywesee GmbH
Settings
|
Help
|
FAQ
|
Login
|
Contact
|
Home
